|
Compound class:
Synthetic organic
Comment: This tricyclic compound is claimed as a dual phosphodiesterase (PDE) 3/4 inhibitor in patent WO2021143841A1 (Chia Tai Tianqing Pharmaceutical) [3]. The compound is proposed for the treatment of chronic inflammatory respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD) via inhalation as a nebulized formulation. Sun Biopharm Group who own the patent holder, have a declared clinical candidate PDE3/4 inhibitor called TQC3721 in development in China [1-2]. The chemical structure of TQC3721 has not been formally disclosed (as of July 2026).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| In vitro and animal studies demonstrate PDE3/4 inhibition and anti-inflammatory activity. |